# A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Source: https://onco.cc/trials/nct04245839/  
OnCo record `nct04245839` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fludarabine, Cyclophosphamide in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT04245839 by Celgene, with 276 participants planned, started 2020-07-14 and due to reach its primary completion in 2031-09-30. Interventions recorded: Fludarabine, Cyclophosphamide, JCAR017. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04245839
- Phase: 2
- Setting: A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
- Sponsor: Celgene
- Enrolled: 276

## Sources

- ClinicalTrials.gov NCT04245839: https://clinicaltrials.gov/study/NCT04245839

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04245839.json